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Background: Patient reported outcomes are accepted as important outcome measures in rheumatology. The
fluctuating symptoms in patients with rheumatic diseases have serious implications for sample size in clinical trials.
We estimated the effects of measuring the outcome 1-5 times on the sample size required in a two-armed trial.
Findings: In a randomized controlled trial that evaluated the effects of a mindfulness-based group intervention for
patients with inflammatory arthritis (n=71), the outcome variables Numerical Rating Scales (NRS) (pain, fatigue,
disease activity, self-care ability, and emotional wellbeing) and General Health Questionnaire (GHQ-20) were
measured five times before and after the intervention. For each variable we calculated the necessary sample sizes
for obtaining 80% power (α=.05) for one up to five measurements.
Two, three, and four measures reduced the required sample sizes by 15%, 21%, and 24%, respectively. With three
(and five) measures, the required sample size per group was reduced from 56 to 39 (32) for the GHQ-20, from 71
to 60 (55) for pain, 96 to 71 (73) for fatigue, 57 to 51 (48) for disease activity, 59 to 44 (45) for self-care, and 47 to
37 (33) for emotional wellbeing.
Conclusions : Measuring the outcomes five times rather than once reduced the necessary sample size by an
average of 27%. When planning a study, researchers should carefully compare the advantages and disadvantages of
increasing sample size versus employing three to five repeated measurements in order to obtain the required
statistical power.
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Patient reported outcomes (PRO) are accepted as imp-
ortant outcome measures in rheumatology. In patients
with rheumatic diseases the symptoms are fluctuating
[1]. This has serious implications for sample sizes in cli-
nical trials. Since the within-patient variation will be in-
cluded in the total variation, this in turn will increase
the standard deviation and finally require larger sample
sizes.
When planning a clinical trial, the researchers want to
design it so that it has sufficient statistical power to* Correspondence: Geir.Smedslund@diakonsyk.no
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distribution, and reproduction in any mediumdetect a clinically relevant difference between groups [2].
When researchers draw conclusions, they want to avoid
committing a Type II error, which basically means con-
cluding that there is no difference when there is in fact a
difference. Power is the probability of not making a Type
II error. The Type II error probability (β) is by conven-
tion set to .2, which equals a power of 80 percent. Most
often researchers will compute the sample size necessary
for detecting the minimal clinically important difference
(MCID) when planning a trial. At the same time, they
need to minimize the Type I error probability to avoid
concluding with an effect when the null hypothesis is
true. The required sample sizes may often be hard to ob-
tain for different reasons. Keen et al. investigated thetral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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found that a substantial number of randomized controlled
trials of adult rheumatic diseases were underpowered [3].
Approximately 50% of the RCTs with negative results
were underpowered, and these trials may not have been of
sufficient sample size to detect clinically meaningful treat-
ment effects.
One way of increasing power is to reduce the standard
deviation (SD) of the outcome of interest. This can be
achieved by measuring the outcomes on several occa-
sions on the same patient and averaging the measure-
ments. Thus, it is possible to increase power without
including additional patients in the trial. In a previous
prospective observational study we simulated how the
within-subject variation decreases when the number of
measurements is varied between 1 and 42 [2]. Consider-
ing the findings that five measurements per patient can
be optimal for reducing the SD [2], we decided to em-
ploy this concept in a recently published trial [4]. The
aim of the present study was to show how much the re-
quired sample size decreased when the number of mea-
surements was increased from one up to five.
Methods
In a randomized controlled trial that evaluated the ef-
fects of a mindfulness-based group intervention for pa-
tients with inflammatory arthritis (n = 71), the primary
outcome variable was psychological distress measured
by the General Health Questionnaire (GHQ-20), wher-
eas secondary outcomes included pain, fatigue, disease
activity, self-care ability, and emotional wellbeing mea-
sured by Numerical Rating Scales (NRS) [4]. The items
on the GHQ are scored on a four-point Likert scale
(0 to 3) which gives a possible sum score of between 0
(no distress at all) and 60 (much more distress than
usual) [5,6] The GHQ-20 has been validated and used in
various samples of chronically ill persons in Norway. [4].
The NRS is a 10 cm horizontal line, numbered from
zero to ten and anchored with two extremes at the ends
(e.g. 0 = no pain/fatigue and 10 = intolerable pain/fa-
tigue). The respondents are asked to tick the number
that best indicate their condition [7]. During the baseline
period each variable was measured at two-week intervals
five times. The first four measurements were conducted
by telephone interviews, and the fifth measurement by a
questionnaire sent to participants with a postage-paid
return envelope.
Although there are several possible statistical methods
available for repeated measurements, we chose to do
it as simple as possible by computing a pooled mean.
Thus, for each outcome measure, we calculated the SD
attained by pooling two, three, four, and five measure-
ments as compared to the single measurement. We cal-
culated required sample sizes assuming α=.05 and β=.2(power: 80%). Because there were no clear recommenda-
tions in the literature about what a clinically relevant
change in the GHQ-20 might be, we performed a pilot
study prior to the RCT. Based on the results of this pilot,
we hypothesised that the RCT would detect a difference
between groups of 4.5 in GHQ-20 with an estimated SD
of 3.9, and a probability of a slight improvement of 0.9
in the control group. Thus, in the present study the
value of 4.5 was used as a minimal clinical important
difference (MCID) for the GHQ-20, and a MCID of 1
was used for the NRS scales. For each variable we calcu-
lated the necessary sample sizes for obtaining 80% power
both for the single measurement case and for the two-
three-, four-, and five measurement cases. In order to
check whether choice of MCID would alter the results,
we ran additional analyses using MCIDs of 6 for the
GHQ and 2 for the NRS scales.Findings
Measuring the outcomes five times rather than once
reduced the necessary sample size by an average of 27%
for all outcomes (Figure 1). Using two, three, and four
measurements reduced the required sample size by 15%,
21%, and 24%, respectively. When we measured the out-
comes three (five) times, the sample size per group was
reduced from 51 to 39 (32) for the GHQ-20, from 74 to
60 (55) for pain, 99 to 71 (73) for fatigue, 68 to 51 (48)
for disease activity, 66 to 44 (45) for self-care, and 52 to
37 (33) for emotional wellbeing (Table 1). Using different
MCIDs produced essentially the same results (data not
shown).Discussion
To our knowledge this is the first study within rheuma-
tology using empirical data from a randomized con-
trolled trial to estimate the effects of 1–5 measurements
on the required sample size. We found that five mea-
surements reduced the required sample size by 27% on
average. Considering that a substantial number of rando-
mized controlled trials of adult rheumatic diseases were
underpowered [3], researchers should carefully consider
the advantages of employing five measurements in order
to obtain the required statistical power. However, a
major reduction (21%) was achieved by three measure-
ments only. Introducing a fourth and fifth measurement
reduced the required sample size relatively less. In fact,
for two outcomes (fatigue and self-care) the standard
deviation and the required sample size increased mar-
ginally when adding a fourth and fifth measurement. For
all other outcomes there was a monotonic decreasing
standard deviation and required sample size as the num-
ber of measurements was increased up to five. Thus,





























   







Figure 1 Percent reduction in required sample size as a function of increasing number of measurements per patient.
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perspective.
A possible explanation for the two exceptions to our
general findings described above can be found in an art-
icle by Winkens et al. [8]. They reported that the covari-
ance structure can greatly influence the optimal number
of measurements. In their data, two measurements often
yielded highly efficient treatment effect estimators. More
measurements were needed if a) the covariance structure
was compound symmetric or b) the structure approa-
ched compound symmetry (CS) and the correlation be-
tween two measurements did not exceed 0.80 or c) the
correlation did not exceed 0.60, if the time lag went to
zero. Zhang and Ahn [9] also found that more measu-
rements are needed under the CS correlation and that
the magnitude of sample size reduction quickly decreasesTable 1 Standard deviation and required sample size (percen
Standard d




Disease activity 1.89 1.80
Self-care 1.92 1.77
Emotional well-being 1.73 1.65
Required sample size (percent reduction) per group
Variable 1 measure 2 measures
GHQ 56 44 (21)
Pain 71 61 (14)
Fatigue 96 78 (19)
Disease activity 57 51 (11)
Self-care 59 50 (15)
Emotional well-being 47 43 (9)when the number of measurements per subjects increases
beyond 4.
It seems that five measurements have a larger effect
on the required sample size for the GHQ than for the
NRS scales. This may be because the GHQ consists of
20 items, each of which have a variance, while the NRS
is a single-item scale.
Some limitations of using repeated measurements need
to be considered. Completing questionnaires may be both
time consuming and strenuous for the patients. The be-
nefit of increasing the number of measurements should
therefore be balanced against the burden on the respon-
dents. In the present study, we decided to use telephone
interviews for four of the measurements, assuming that
the burden on patients would be less if they were called
than if they were asked to fill in and return questionnaires,t reduction) as a function of 1–5 measurements
eviation







3 measures 4 measures 5 measures
39 (30) 36 (36) 32 (43)
60 (15) 58 (18) 55 (23)
71 (26) 72 (25) 73 (24)
51 (11) 50 (12) 48 (16)
44 (25) 45 (24) 45 (24)
37 (21) 34 (28) 33 (30)
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views may have introduced a recall bias and thereby influ-
enced the within-person variation.
Another limitation is the costs of completing the mea-
surements in terms of time and personnel needed, which
should be balanced against the costs of including a lar-
ger sample. Also the choice of MCID can be discussed.
However, the size of MCID did not influence the relative
reduction in sample size in our analyses.
We end with a cautionary note. As one of the revie-
wers pointed out: “. . .when planning a longitudinal study
with repeated measurements, researchers must estimate
sample size a priori (by fixing alpha, beta, MCID, number
of repeated measurements, variability of the outcome, cor-
relation (correlation structure)”. In other words, they have
to assume a model of the data. This means that other
researchers cannot simply apply our reported empiri-
cal sample size reductions for other outcomes in other
contexts.
Conclusions
We found that using up to three measurements per pa-
tient substantially reduced the required sample size for
all measures in this study. Adding a fourth or fifth mea-
sure resulted in a smaller reduction. When planning a
trial, researchers should carefully compare the advanta-
ges and disadvantages of increasing sample size versus
employing multiple measurements in order to obtain the
required statistical power.
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